miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR

HCC is a common malignancy worldwide and surgery or reginal treatments are deemed insufficient for advanced-stage disease. Sorafenib is an inhibitor of many kinases and was shown to benefit advanced HCC patients. However, resistance emerges soon after initial treatment, limiting the clinical benefit...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cell Death Dis
Huvudupphovsmän: Ji, Lin, Lin, Zhongjie, Wan, Zhe, Xia, Shunjie, Jiang, Shi, Cen, Dong, Cai, Liuxin, Xu, Junjie, Cai, Xiujun
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group UK 2020
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7170966/
https://ncbi.nlm.nih.gov/pubmed/32313144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-020-2413-4
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk